Nihar Masurkar
Research Subjects
Nihar Masurkar has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Ahmed Shelbaya
Pfizer Inc
1 shared publicationAlison Bulkley
Oracle Life Sciences, Austin, TX
1 shared publicationAstrid Ottosson Wadlund
Janssen‐Cilag AB Solna Sweden
1 shared publication- Cecile Morasso
Oracle Life Sciences, Paris, France
1 shared publication Chiho Ono
Pfizer Japan Inc
1 shared publicationCécile Pacheco
Cerner Enviza France SAS Paris France
1 shared publication
Latest Publications
- Open Access
- 11 February 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (3) , 102519
Treatment Patterns Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate Cancer: A Global Real-World Study
- 11 February 2026
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 24 (3) , 102519
Open AccessTreatment Patterns Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate Cancer: A Global Real-World Study
- Open Access
- 12 June 2024
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (25) , 1837-1850
A descriptive analysis of real-world oncology biosimilar use in Japan
Aim: To describe patient and treatment characteristics associated with bevacizumab BS-Pfizer, rituximab BS-Pfizer and trastuzumab BS-Pfizer and their reference products in Japan.
- 12 June 2024
- Published by Taylor & Francis in Future Oncology
- Vol. 20 (25) , 1837-1850
Open AccessA descriptive analysis of real-world oncology biosimilar use in Japan
Aim: To describe patient and treatment characteristics associated with bevacizumab BS-Pfizer, rituximab BS-Pfizer and trastuzumab BS-Pfizer and their reference products in Japan.
- Open Access
- 12 July 2022
- Published by Wiley in European Journal of Haematology
- Vol. 109 (4) , 388-397
Real‐world study on adoption of standard‐of‐care for transplant‐eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy
Objectives This non-interventional observational study described the current standard-of-care for transplant-eligible newly diagnosed multiple myeloma (TE-NDMM) patients in France, Germany, Spain, and Italy, and recorded the evolution in regimen adoption in distinct elements of frontline treatment during 2017-2020/2021. Methods Clinical information on ongoing (I) or previous (II) TE-NDMM patients was extracted from the Cancerology database. Proportions of patients receiving regimens in each element and the evolution in regimen adoption were determined for the entire population and each country. Results Most common induction regimens among I patients were VRd in France (75.3%) and Spain (44.1%), VTd in Italy (65.2%), and regimens other than VRd/VTd/VCd in Germany. Maintenance was ongoing/planned for 78.3%, 62.3%, 65.2%, and 61.4% patients in France, Germany, Spain, and Italy, respectively. Among II patients, VRd induction increased from 27.0% in 2017 to 65.7% in 2019 in France, remained relatively low in Spain and Germany, and not present in Italy. In Italy and Spain, VTd induction declined from 72.4% and 58.3% in 2017 to 52.8% and 17.3% in 2019, respectively. VCd induction in Germany declined from 85.2% in 2017 to 64.1% in 2019. Conclusion The use of bortezomib triplets in induction varied markedly over time and between selected countries.
- 12 July 2022
- Published by Wiley in European Journal of Haematology
- Vol. 109 (4) , 388-397
Open AccessReal‐world study on adoption of standard‐of‐care for transplant‐eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy
Objectives This non-interventional observational study described the current standard-of-care for transplant-eligible newly diagnosed multiple myeloma (TE-NDMM) patients in France, Germany, Spain, and Italy, and recorded the evolution in regimen adoption in distinct elements of frontline treatment during 2017-2020/2021. Methods Clinical information on ongoing (I) or previous (II) TE-NDMM patients was extracted from the Cancerology database. Proportions of patients receiving regimens in each element and the evolution in regimen adoption were determined for the entire population and each country. Results Most common induction regimens among I patients were VRd in France (75.3%) and Spain (44.1%), VTd in Italy (65.2%), and regimens other than VRd/VTd/VCd in Germany. Maintenance was ongoing/planned for 78.3%, 62.3%, 65.2%, and 61.4% patients in France, Germany, Spain, and Italy, respectively. Among II patients, VRd induction increased from 27.0% in 2017 to 65.7% in 2019 in France, remained relatively low in Spain and Germany, and not present in Italy. In Italy and Spain, VTd induction declined from 72.4% and 58.3% in 2017 to 52.8% and 17.3% in 2019, respectively. VCd induction in Germany declined from 85.2% in 2017 to 64.1% in 2019. Conclusion The use of bortezomib triplets in induction varied markedly over time and between selected countries.